{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:11:56Z","timestamp":1786990316169,"version":"build-2736575974"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"NIH","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.idc.2019.02.007","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T12:13:32Z","timestamp":1555503212000},"page":"593-609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Vaccination of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient"],"prefix":"10.1016","volume":"33","author":[{"given":"Mini","family":"Kamboj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika K.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.idc.2019.02.007_bib1","first-page":"271","article-title":"Cancer treatment and survivorship statistics, 2016","volume":"66","author":"Miller","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.idc.2019.02.007_bib2","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbmt.2013.07.020","article-title":"Prevalence of hematopoietic cell transplant survivors in the United States","volume":"19","author":"Majhail","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.idc.2019.02.007_bib3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.15585\/mmwr.mm6605e2","article-title":"Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older - United States, 2017","volume":"66","author":"Kim","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.idc.2019.02.007_bib4","unstructured":"Kotton CN, Kroger AT, Freedman DO. Chapter 8: immunocompromised travelers. In: Centers for Disease Control and Prevention, editor. The CDC health information for international travel (The Yellow Book). 2018. Available at: https:\/\/wwwnc.cdc.gov\/travel\/yellowbook\/2018\/advising-travelers-with-specific-needs\/immunocompromised-travelers. Accessed October 24, 2018."},{"issue":"10","key":"10.1016\/j.idc.2019.02.007_bib5","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.idc.2019.02.007_bib6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2019.02.007_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/bmt.2009.263","article-title":"Vaccination of hematopoietic cell transplant recipients","volume":"44","author":"Ljungman","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.idc.2019.02.007_bib8","article-title":"Epidemiology and prevention of vaccine-preventable diseases","year":"2015"},{"issue":"2","key":"10.1016\/j.idc.2019.02.007_bib9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/21645515.2017.1264797","article-title":"Recommended vaccinations for asplenic and hyposplenic adult patients","volume":"13","author":"Bonanni","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"23","key":"10.1016\/j.idc.2019.02.007_bib10","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2015-12-550475","article-title":"How I vaccinate blood and marrow transplant recipients","volume":"127","author":"Carpenter","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.idc.2019.02.007_bib11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.idc.2019.02.007_bib12","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/cid\/civ272","article-title":"Clinical outcomes associated with respiratory virus detection before allogeneic hematopoietic stem cell transplant","volume":"61","author":"Campbell","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2019.02.007_bib13","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1164\/rccm.201804-0681OC","article-title":"Clinical significance of upper airway virus detection in critically ill hematology patients","volume":"199","author":"Legoff","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.idc.2019.02.007_bib14","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1086\/425004","article-title":"Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy","volume":"39","author":"Nichols","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2019.02.007_bib15","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.bbmt.2005.07.007","article-title":"Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies","volume":"11","author":"Martino","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.idc.2019.02.007_bib16","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3324\/haematol.2011.041913","article-title":"Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients","volume":"96","author":"Ljungman","year":"2011","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.idc.2019.02.007_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/sj.bmt.1703139","article-title":"Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for blood and marrow transplantation","volume":"28","author":"Ljungman","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.idc.2019.02.007_bib18","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3109\/10428194.2010.508823","article-title":"Novel influenza A (H1N1) in patients with hematologic disease","volume":"51","author":"Wei","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.idc.2019.02.007_bib19","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.bbmt.2010.07.004","article-title":"The clinical impact of infection with swine flu (H1N109) strain of influenza virus in hematopoietic stem cell transplant recipients","volume":"17","author":"George","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.idc.2019.02.007_bib20","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.bbmt.2010.07.018","article-title":"Novel H1N1 influenza in hematopoietic stem cell transplantation recipients: two centers' experiences","volume":"17","author":"Espinosa-Aguilar","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.idc.2019.02.007_bib21","first-page":"257","article-title":"2009 H1N1 influenza infection in cancer patients and hematopoietic stem cell transplant recipients","volume":"60","author":"Redelman-Sidi","year":"2010","journal-title":"J\u00a0Infect"},{"issue":"3","key":"10.1016\/j.idc.2019.02.007_bib22","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.bbmt.2015.11.015","article-title":"Outcomes of influenza infections in hematopoietic cell transplant recipients: application of an immunodeficiency scoring index","volume":"22","author":"Kmeid","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.idc.2019.02.007_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/bmt.2011.12","article-title":"The clinical features and outcome of 2009 H1N1 influenza infection in allo-SCT patients: a British Society of Blood and Marrow Transplantation study","volume":"47","author":"Protheroe","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.idc.2019.02.007_bib24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/TP.0b013e3181772a75","article-title":"Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation","volume":"86","author":"Avetisyan","year":"2008","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.idc.2019.02.007_bib25","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/cid\/ciy294","article-title":"A\u00a05-year prospective multicenter evaluation of influenza infection in transplant recipients","volume":"67","author":"Kumar","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2019.02.007_bib26","article-title":"Clinical effectiveness of influenza vaccination after allogeneic hematopoietic stem cell transplantation: a cross-sectional prospective observational study","author":"Pinana","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2019.02.007_bib27","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/sj.bmt.1705159","article-title":"The benefit of influenza vaccination after bone marrow transplantation","volume":"36","author":"Machado","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.idc.2019.02.007_bib28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/tid.12054","article-title":"European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN","volume":"15","author":"Engelhard","year":"2013","journal-title":"Transpl Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2019.02.007_bib29","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/bmt.2009.254","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface","volume":"44","author":"Tomblyn","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2019.02.007_bib30","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/irv.12084","article-title":"Influenza vaccination for immunocompromised patients: summary of a systematic review and meta-analysis","volume":"7","author":"Beck","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"issue":"3","key":"10.1016\/j.idc.2019.02.007_bib31","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.bbmt.2015.12.003","article-title":"Randomized double-blind study of the safety and immunogenicity of standard-dose trivalent inactivated influenza vaccine versus high-dose trivalent inactivated influenza vaccine in adult hematopoietic stem cell transplantation patients","volume":"22","author":"Halasa","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.idc.2019.02.007_bib32","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of high-dose versus standard-dose influenza vaccine in older adults","volume":"371","author":"DiazGranados","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.idc.2019.02.007_bib33","first-page":"1","article-title":"Antibody response to a two-dose regimen of influenza vaccine in allogeneic T\u00a0cell-depleted and autologous BMT recipients","volume":"11","author":"Engelhard","year":"1993","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.idc.2019.02.007_bib34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbmt.2012.08.015","article-title":"A\u00a0randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation","volume":"19","author":"Karras","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.idc.2019.02.007_bib35","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3324\/haematol.2011.040386","article-title":"Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A\/09\/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients","volume":"96","author":"Mohty","year":"2011","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.idc.2019.02.007_bib36","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/bmt.2017.24","article-title":"A\u00a0pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients","volume":"52","author":"Natori","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.idc.2019.02.007_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6703a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices-United States, 2018-19 Influenza Season","volume":"67","author":"Grohskopf","year":"2018","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"10.1016\/j.idc.2019.02.007_bib38","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/bmt.2015.47","article-title":"Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study","volume":"50","author":"Ambati","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.idc.2019.02.007_bib39","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1086\/313663","article-title":"Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients","volume":"30","author":"Pauksen","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"25","key":"10.1016\/j.idc.2019.02.007_bib40","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa1608862","article-title":"Efficacy of recombinant influenza vaccine in adults 50 years of age or older","volume":"376","author":"Dunkle","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.idc.2019.02.007_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6602a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices - United States, 2017-18 influenza season","volume":"66","author":"Grohskopf","year":"2017","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"10.1016\/j.idc.2019.02.007_bib42","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/jjco\/hyw020","article-title":"A\u00a0prospective study on the efficacy of two-dose influenza vaccinations in cancer patients receiving chemotherapy","volume":"46","author":"Sanada","year":"2016","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10.1016\/j.idc.2019.02.007_bib43","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2141.2005.05582.x","article-title":"Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study","volume":"130","author":"Ljungman","year":"2005","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1016\/j.idc.2019.02.007_bib44","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1182\/blood-2011-08-372649","article-title":"Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6\u00a0months after treatment","volume":"118","author":"Yri","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.idc.2019.02.007_bib45","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/cid\/ciy175","article-title":"Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer","volume":"67","author":"Varughese","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2019.02.007_bib46","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.3324\/haematol.2017.164285","article-title":"Ibrutinib may impair serological responses to influenza vaccination","volume":"102","author":"Douglas","year":"2017","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.idc.2019.02.007_bib47","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1001\/jamaoncol.2016.2437","article-title":"Seasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"2","author":"Sun","year":"2016","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.idc.2019.02.007_bib48","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/cid\/cix836","article-title":"Prevalence of Hypogammaglobulinemia in Adult Invasive Pneumococcal Disease","volume":"66","author":"Cowan","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2019.02.007_bib49","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/cid\/civ803","article-title":"Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs","volume":"62","author":"Shigayeva","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2019.02.007_bib50","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/cid\/cix739","article-title":"Trends in invasive pneumococcal disease in cancer patients after the introduction of 7-valent pneumococcal conjugate vaccine: a 20-year longitudinal study at a major urban cancer center","volume":"66","author":"Lee","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2019.02.007_bib51","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.idc.2019.02.007_bib52","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1086\/523583","article-title":"A\u00a0randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients","volume":"45","author":"Kumar","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2019.02.007_bib53","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood-2006-06-032284","article-title":"Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation","volume":"109","author":"Meisel","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.idc.2019.02.007_bib54","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1086\/598324","article-title":"Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2019.02.007_bib55","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/bmt.2015.42","article-title":"Long-term persistence of the immune response to antipneumococcal vaccines after Allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial","volume":"50","author":"Cordonnier","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.idc.2019.02.007_bib56","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/sj.bmt.1704870","article-title":"Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT","volume":"35","author":"Ljungman","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.idc.2019.02.007_bib57","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/cid\/civ287","article-title":"Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged\u00a0>\/=2 years: an open-label study","volume":"61","author":"Cordonnier","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2019.02.007_bib58","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1158\/1078-0432.CCR-11-1221","article-title":"Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses","volume":"18","author":"Noonan","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.idc.2019.02.007_bib59","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/infdis\/173.1.256","article-title":"Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease","volume":"173","author":"Chan","year":"1996","journal-title":"J\u00a0Infect Dis"},{"issue":"37","key":"10.1016\/j.idc.2019.02.007_bib60","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Tomczyk","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"10.1016\/j.idc.2019.02.007_bib61","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/bjc.2017.124","article-title":"Herpes zoster risk after 21 specific cancers: population-based case-control study","volume":"116","author":"Hansson","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.idc.2019.02.007_bib62","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12879-015-0810-6","article-title":"The epidemiology of herpes zoster and its complications in Medicare cancer patients","volume":"15","author":"Yenikomshian","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"27","key":"10.1016\/j.idc.2019.02.007_bib63","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1016\/j.vaccine.2018.05.078","article-title":"Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection","volume":"36","author":"Alexander","year":"2018","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.idc.2019.02.007_bib64","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"22","key":"10.1016\/j.idc.2019.02.007_bib65","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.idc.2019.02.007_bib66","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2019.02.007_bib67","unstructured":"de la Serna J, Campora L, Chandrasekar P, et\u00a0al. Efficacy and safety of an adjuvanted herpes zoster subunit vaccine in autologous hematopoietic stem cell transplant recipients 18 years of age or older: first results of the phase 3 randomized, placebo-controlled ZOE-HSCT clinical trial. Abstract presented at the BMT Tandem Meeting. Salt Lake City, UT, February 25, 2018.."},{"issue":"10135","key":"10.1016\/j.idc.2019.02.007_bib68","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0140-6736(18)30631-7","article-title":"Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Winston","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.idc.2019.02.007_bib69","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.bbmt.2018.04.003","article-title":"Varicella zoster virus reactivation in adult survivors of hematopoietic cell transplantation: how do we best protect our patients?","volume":"24","author":"Lee","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.idc.2019.02.007_bib70","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bbmt.2016.12.620","article-title":"Herpes zoster in autologous hematopoietic cell transplant recipients in the era of acyclovir or valacyclovir prophylaxis and novel treatment and maintenance therapies","volume":"23","author":"Sahoo","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.idc.2019.02.007_bib71","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.bbmt.2008.09.004","article-title":"Recovery of varicella-zoster virus-specific T\u00a0cell immunity after T\u00a0cell-depleted allogeneic transplantation requires symptomatic virus reactivation","volume":"14","author":"Distler","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.idc.2019.02.007_bib72","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/bloodadvances.2016000836","article-title":"Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir\/valacyclovir followed by vaccination","volume":"1","author":"Jamani","year":"2016","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.idc.2019.02.007_bib73","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.bbmt.2013.11.013","article-title":"Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients","volume":"20","author":"Issa","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.idc.2019.02.007_bib74","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/ajh.22196","article-title":"Experience with use of Zostavax((R)) in patients with hematologic malignancy and hematopoietic cell transplant recipients","volume":"87","author":"Naidus","year":"2012","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.idc.2019.02.007_bib75","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41409-018-0112-x","article-title":"Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation","volume":"53","author":"Pandit","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.idc.2019.02.007_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6702a1","article-title":"Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"67","author":"Liang","year":"2018","journal-title":"MMWR Recomm Rep"},{"issue":"12","key":"10.1016\/j.idc.2019.02.007_bib77","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.bbmt.2009.07.018","article-title":"Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation","volume":"15","author":"Small","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.idc.2019.02.007_bib78","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/bmt.2012.141","article-title":"Live (vaccines) from New York","volume":"48","author":"Forlenza","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.idc.2019.02.007_bib79","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1179\/1607845414Y.0000000174","article-title":"Evaluation of the immune status against measles, mumps, and rubella in adult allogeneic hematopoietic stem cell transplantation recipients","volume":"20","author":"Kawamura","year":"2015","journal-title":"Hematology"},{"issue":"37","key":"10.1016\/j.idc.2019.02.007_bib80","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1016\/j.vaccine.2014.06.088","article-title":"Measles and mumps outbreaks in the United States: Think globally, vaccinate locally","volume":"32","author":"Whitaker","year":"2014","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.idc.2019.02.007_bib81","doi-asserted-by":"crossref","first-page":"509","DOI":"10.15585\/mmwr.mm6619a6","article-title":"Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine - advisory committee on immunization practices, 2016","volume":"66","author":"Patton","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"10.1016\/j.idc.2019.02.007_bib82","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1182\/blood-2002-03-0832","article-title":"Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation","volume":"101","author":"Molrine","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.idc.2019.02.007_bib83","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/jtm.12013","article-title":"International travel patterns and travel risks of patients diagnosed with cancer","volume":"20","author":"Mikati","year":"2013","journal-title":"J\u00a0Travel Med"},{"issue":"1","key":"10.1016\/j.idc.2019.02.007_bib84","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jtm.12166","article-title":"International travel patterns and travel risks for stem cell transplant recipients","volume":"22","author":"Mikati","year":"2015","journal-title":"J\u00a0Travel Med"},{"key":"10.1016\/j.idc.2019.02.007_bib85","unstructured":"CDC. Travelers health. Available at: Healthhttps:\/\/wwwnc.cdc.gov\/travel\/. Accessed: October 28, 2018."},{"issue":"3","key":"10.1016\/j.idc.2019.02.007_bib86","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/infdis\/jix564","article-title":"Immunogenicity and Safety of Yellow Fever Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients After Withdrawal of Immunosuppressive Therapy","volume":"217","author":"Sicre de Fontbrune","year":"2018","journal-title":"J\u00a0Infect Dis"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552019300108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552019300108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:15:37Z","timestamp":1760195737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552019300108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0891552019300108"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2019.02.007","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2019.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}